Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04605796

A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)

Advanced Hepatocellular Carcinoma (HCC) Clinical Trial

Official title:
A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)

Clinical Trial Summary

This is an open-label, single-arm, national multicenter phase II clinical study to preliminarily observe and evaluate the efficacy and safety of Toripalimab combined with Bevacizumab as the first-line therapy for advanced HCC The study will use safety/tolerability and ORR as the primary study objectives and indicators, and plans to enroll about 50-60 patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04605796
Study type Interventional
Source Shanghai Junshi Bioscience Co., Ltd.
Contact
Status Active, not recruiting
Phase Phase 2
Start date April 10, 2020
Completion date December 31, 2022
View Details
See also
  Status Clinical Trial Phase
Terminated NCT04985136 - A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC) Phase 3
Recruiting NCT02509169 - Trans-catheter Arterial Embolization Combined With p53 Gene Therapy for Treatment of Advanced Hepatocellular Carcinoma Phase 2
Active, not recruiting NCT04723004 - Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC Phase 3
Completed NCT02814461 - The Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for HCC Phase 1
Not yet recruiting NCT04344158 - A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) Phase 3
Completed NCT02906397 - Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma (HCC) Phase 1
Active, not recruiting NCT04523493 - Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC Phase 3
Terminated NCT05375604 - A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From EIther Primary Gastric Cancer or Colorectal Cancer (CRC) Phase 1
Terminated NCT01101906 - A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC Phase 2
Recruiting NCT05862181 - The Comparison Between HepaSphere Drug-eluting Bead Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma
Not yet recruiting NCT06309485 - Phase 2 Study of WGI-0301 in Combination With Sorafenib for Advanced HCC Phase 2
Terminated NCT04212221 - MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients Phase 1/Phase 2